# Study to Evaluate the Safety and Effectiveness of Zostavax™ in Subjects 50 - 59 Years of Age (V211-022)

> **NCT00534248** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 22439 (actual)

## Conditions studied

- Shingles

## Interventions

- **BIOLOGICAL:** Zoster Vaccine, Live (Zostavax™)
- **BIOLOGICAL:** Comparator: Placebo

## Key facts

- **NCT ID:** NCT00534248
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2010-01
- **Final completion:** 2010-01
- **Target enrollment:** 22439 (ACTUAL)
- **Last updated:** 2017-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00534248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00534248, "Study to Evaluate the Safety and Effectiveness of Zostavax™ in Subjects 50 - 59 Years of Age (V211-022)". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT00534248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*